Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors

Adlai Nortye Announces First Patient Dosed In Phase I Clinical Trial Of The Orally Available, Small Molecule Pd L1 Inhibitor An4005 For Advanced Tumors

Facebook Comments

Leave a Reply

CommentLuv badge